Year: 2022

news_6

Sensorion Announces Approval in Australia to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation

Australian approval follows recent trial approval by regulatory authorities in France MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN), a...

Takeda_Red_Logo_2021

Takeda’s TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years

Children Ages 2 to <12 Experienced 94.8% Fewer Hereditary Angioedema (HAE) Attacks During Treatment with TAKHZYRO Over the 52-Week Treatment...